SCHEMBL22801021

SCHEMBL22801021

O=C(OCc1ccccc1)c1ccc2c(c1)CNCC2

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.51
SLC6A2 P23975 1/20 0.51
SLC6A3 Q01959 1/20 0.51
KMT2A Q03164 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
SRD5A1 P18405 1/20 0.49
SRD5A2 P31213 1/20 0.49
ALDH1A1 P00352 3/20 0.49
MAPT P10636 2/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
CFD P00746 1/20 0.48
F11 P03951 1/20 0.48
HPGD P15428 1/20 0.46
KDM4E B2RXH2 1/20 0.45
PNMT P11086 1/20 0.45
ACHE P22303 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22801018 0.95 LMNA (0.51) LMNASLC6A2SLC6A3KMT2ATDP1
Hydrochloric Acid SCHEMBL31370668 0.94 LMNA (0.50) LMNASLC6A2SLC6A3KMT2ATDP1
SCHEMBL22801022 0.92 KMT2A (0.54) LMNASLC6A2SLC6A3KMT2ATDP1
SCHEMBL22801020 0.89 TDP1 (0.57) LMNASLC6A2SLC6A3KMT2ATDP1
SCHEMBL22801019 0.88 LMNA (0.49) LMNASLC6A2SLC6A3KMT2ATDP1
SCHEMBL7445675 0.82 SRD5A1 (0.53) LMNASLC6A2SLC6A3KMT2ATDP1
SCHEMBL30782362 0.81 CA12 (0.49) LMNASLC6A2SLC6A3KMT2ASRD5A1
SCHEMBL19590797 0.81 CA12 (0.49) LMNASLC6A2SLC6A3KMT2ASRD5A1
SCHEMBL23762151 0.81 TDP1 (0.47) LMNASLC6A2SLC6A3KMT2ATDP1
SCHEMBL20375431 0.81 ROCK2 (0.46) CFDF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688779-A2 NOVEL COMPOUNDS AND USES THEREOF Acelink Therapeutics, Inc. (US) 2026-02-11 EP disclosed
WO-2024211244-A2 NOVEL COMPOUNDS AND USES THEREOF ACELINK THERAPEUTICS, INC. (US) 2024-10-10 WO disclosed
US-11332468-B2 Azaindole derivatives as Rho-kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2022-05-17 US disclosed
US-20200392133-A1 AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2020-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332468-B2 Azaindole derivatives as Rho-kinase inhibitors ROCK1, ROCK2, RHOA LMNA 3702/4885SLC6A2 3437/4885SLC6A3 4145/4885
US-20200392133-A1 AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS ROCK1, ROCK2, RHOA LMNA 3702/4885SLC6A2 3437/4885SLC6A3 4145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.